ArticleFrontiers in cardiovascular medicine2026
Ethanol infusion of the vein of Marshall reduces localized voltage but preserves mitral isthmus conduction velocity.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ethanol infusion of the vein of Marshall (EIVOM) has emerged as a promising adjunct to pulmonary vein isolation (PVI) for atrial fibrillation (AF). Methods: Patients undergoing catheter ablation for persistent AF (>3 months) were enrolled in this study. After PVI, high-density mapping (HD-Grid, Abbott, St Paul, MN) was performed during coronary sinus pacing (100 bpm) to assess left atrial conduction velocity (CV) and voltage. EIVOM was then performed (1-3 mL ethanol × 3 doses), followed by repeat mapping. The CV and voltage were analyzed in the left lateral wall (mitral isthmus/appendage base), with ≥300 points collected per region. A post-EIVOM electrophysiological study with isoprenaline was conducted to induce arrhythmias. Results: Twenty patients with AF (mean age, 64.30 [SD, 7.97] years, five women [25.0%]) with 24 (interquartile range: 6-60) months of AF duration underwent EIVOM (7.8 ± 2.1 mL). Voltage dropped from 1.92 (1.12-2.61) to 1.24 (0.91-2.05) mV postprocedure ( Conclusions: In the acute setting, EIVOM induces localized voltage reduction in the atrial ridge regions without markedly affecting conduction velocity in the mitral isthmus areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.